Press Releases

 FOR IMMEDIATE RELEASE HEADLINE Extended-Release Oral Minoxidil (VDPHL01) Shows Promise as New Treatment for Pattern Hair Loss, Announces New York Dermatologist SUMMARY VDPHL01, a novel extended-release oral minoxidil formulation, is advancing through late-stage clinical trials and may offer a more effective and better-tolerated option for patients with pattern hair loss, according to New York dermatologist Dr. Dennis Porto. BACKGROUND: PATTERN HAIR LOSS Pattern hair loss (androgenetic alopecia) affects millions of men and women and remains one of the most common conditions seen in dermatology. Standard therapies such as topical minoxidil and off-label oral minoxidil have provided varying degrees of benefit, but adherence, scalp irritation, inconsistent absorption, and pharmacokinetic limitations often reduce their overall effectiveness. Immediate-release oral minoxidil reaches high serum concentrations quickly and declines within hours, which can increase the risk of side effects ...

 FOR IMMEDIATE RELEASE December 4, 2025 HEADLINE PP-405 Gains Attention as a Novel Small-Molecule Therapy for Hair Loss Following Early Clinical Signals SUMMARY PP-405, an investigational topical small-molecule therapy for hair loss, is drawing interest after early clinical data suggested meaningful hair regrowth with a favorable safety profile. Dermatologists are watching closely as this new mechanism advances through clinical development for androgenetic alopecia. BACKGROUND: HAIR LOSS AND THE NEED FOR NEW APPROACHES Hair loss, particularly androgenetic alopecia, is one of the most common and psychologically impactful dermatologic conditions. Despite its prevalence, treatment options remain limited, and many patients experience incomplete response, intolerance, or treatment fatigue with currently available therapies such as minoxidil or finasteride. As a result, there has been increasing focus on novel non-hormonal approaches that directly influence hair follicle biology rathe...

 FOR IMMEDIATE RELEASE HEADLINE Low-Dose Isotretinoin Gains Attention as an Emerging Off-Label Anti-Aging Therapy in Dermatology SUMMARY Low-dose isotretinoin, traditionally used to treat severe acne, is gaining interest as a potential off-label anti-aging therapy. New York dermatologist Dr. Dennis Porto highlights growing enthusiasm among patients and clinicians as studies continue to explore its benefits beyond acne. BACKGROUND: SKIN AGING AND TRADITIONAL RETINOID THERAPIES Skin aging is influenced by intrinsic factors such as time and genetics, as well as extrinsic factors including ultraviolet radiation, pollution, and inflammation. Dermatologists have long relied on topical retinoids like tretinoin to improve fine lines, pigmentation irregularities, and overall skin texture. Topical retinoids remain the gold standard in evidence-based anti-aging skincare, but they are limited by adherence challenges, irritation, and variable penetration through the epidermis. Patients seeking ...